An explanation for this phenomenon comes from the article recently published by Melo-Cardenas et al., in which the authors show that myeloproliferative disease progression is associated with increased IL-13 levels, whereas reducing IL-4 and IL-13 associates with reduced features of such disorders [38]. The gene discussed is IL4; the disease is myeloproliferative disorder.